Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.

British journal of cancer - 4 Feb 2014

Jonker D J, Karapetis C S, Harbison C, O'Callaghan C J, Tu D, Simes R J, Malone D P, Langer C, Tebbutt N, Price T J, Shapiro J, Siu L L, Wong R P W, Bjarnason G, Moore M J, Zalcberg J R, Khambata-Ford S

Abstract excerpt

BACKGROUND: Anti-EGFR antibody, cetuximab, improves overall survival (OS) in K-ras wild-type chemotherapy-refractory colorectal cancer. Epidermal growth factor receptor ligand epiregulin (EREG) gene expression may further predict cetuximab benefit. METHODS: Tumour samples from a phase III clinical trial of cetuximab plus best supportive care (BSC) vs BSC alone (CO.17) were analysed for EREG mRNA gene expression....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Neoplasms
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cetuximab

Share to Clinical Trials, Phase III as Topic

Share to Disease-Free Survival

Share to Epidermal Growth Factor

Share to Neoplasm Staging

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 24335920
DOI: 10.1038/bjc.2013.753
PMCID: PMC3915121

Genes

EREG
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer.PMID 24335920Read ↗

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.Semantic proximity Read ↗

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.Semantic proximity Read ↗

Influence of mRNA expression of epiregulin and amphiregulin on outcome of patients with metastatic colorectal cancer treated with 5-FU/LV plus irinotecan or irinotecan plus oxaliplatin as first-line treatment (FIRE 1-trial).Semantic proximity Read ↗

Anti-EGFR therapy in colorectal cancer: how to choose the right patient.Semantic proximity Read ↗

The Oncology Biomarker Discovery framework reveals cetuximab and bevacizumab response patterns in metastatic colorectal cancerSemantic proximity Read ↗

Prognostic value of amphiregulin and epiregulin mRNA expression in metastatic colorectal cancer patients.Semantic proximity Read ↗

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).Semantic proximity Read ↗

Stem cell property epithelial‐to‐mesenchymal transition is a core transcriptional network for predicting cetuximab (Erbitux™) efficacy in <i>KRAS</i> wild‐type tumor cellsSemantic proximity Read ↗

Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer.Semantic proximity Read ↗

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer.Semantic proximity Read ↗

Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.